ACCENTIA BIOPHARMACEUTICALS ACQUIRES EXCLUSIVE LICENSE FOR AN ADDITIONAL LATE-STAGE RESPIRATORY PRODUCT

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it has entered into an exclusive license with Collegium Pharmaceuticals, Inc. (Collegium) to market in the U.S., a branded intranasal steroid intended for the symptoms of seasonal and perennial allergic rhinitis. This product will be marketed by Accentia's specialty pharmaceutical division, TEAMM Pharmaceuticals. This license will expand Accentia's pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1120162XSL_NEWSML_TO_NEWSML_WEB.xml)